The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
New Post
Indonesia-based PT Telkom discloses two U.S. investigations, including an FCPA inquiry
May 1, 2025
News Alert
New Post
Merit Medical Systems discloses SEC inquiry into its China-based subsidiary
May 1, 2025
News Alert
New Post
Dutch authorities charge Damen Shipyards with bribery and sanctions-related offenses
April 29, 2025
News Alert